Mark Grinstaff, PhD

Mark W. Grinstaff is a Distinguished Professor of Translational Research, Biomedical Engineering, Chemistry, Materials Science and Engineering, and Medicine as well as the Director of the NIH T32 Program in Biomaterials and the Director of the Nanotechnology Innovation Center at Boston University.

Mark received his Ph.D. from the University of Illinois under the mentorship of Professor Kenneth S. Suslick and was an NIH postdoctoral fellow at the California Institute of Technology with Professor Harry B. Gray. Mark's awards include the ACS Nobel Laureate Signature Award, NSF Career Award, Pew Scholar in the Biomedical Sciences, Camille Dreyfus Teacher- Scholar, Alfred P. Sloan Research Fellowship, the Edward M. Kennedy Award for Health Care Innovation, and a Founding Fellow of the National Academy of Inventors. He is an author or co-author on more than 225 peer-reviewed manuscripts, given more than 300 oral presentations, and an inventor or co- inventor on more than 200 issued patents or pending applications. His students and fellows have given more than 125 oral presentations and 350 posters at national and international meetings.

Mark's current research activities involve the synthesis of new macromolecules and biomaterials, self-assembly chemistry, imaging contrast agents, drug delivery, and wound repair. His group pursues highly interdisciplinary research in the areas of biomedical engineering and macromolecular chemistry. The major goal in these research projects is to elucidate the underlying fundamental chemistry and engineering principles and to use that insight to direct our creative and scientific efforts. In one of their current research projects, they are designing, synthesizing, and characterizing novel dendrimers, termed “biodendrimers,” for tissue engineering and biotechnological applications. Currently, they are evaluating these novel biomaterials for the repair of corneal lacerations, for the delivery of anti-cancer drugs, for the delivery of DNA, and as temporary biodegradable scaffolds for cartilage repair. In a second project, they are creating novel polymeric coatings termed “interfacial biomaterials” that control biology on plastic, metal, and ceramic surfaces. In a third project, they are designing new polymeric films and nanoparticles loaded with anticancer drugs for the prevention of recurrent cancer after surgical resection.

Mark is a co-founder of several companies that are commercializing his ideas, and he has several products being sold and used in the clinic.

Professor
Boston University College of Arts and Sciences
Chemistry


Director
Boston University
Nanotechnology Innovation Center (BUnano)


Professor
Boston University College of Engineering
Biomedical Engineering


Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Pulmonary, Allergy, Sleep & Critical Care Medicine

Associate Director for Engineering & Sciences
Boston University
BU-BMC Cancer Center


Member
Boston University
Pulmonary Center


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research


Member
Boston University
Genome Science Institute


Graduate Faculty (Primary Mentor of Grad Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences




Translational Research in Biomaterials
09/01/2022 - 08/31/2027 (Multi-PI)
PI: Mark Grinstaff, PhD
NIH/National Institute of Biomedical Imaging & Bioengineering
2T32EB006359-13

Supratherapeutic PTX Buttresses Reduce Locoregional Recurrence Rates Following Surgery for Soft Tissue Sarcomas
08/01/2022 - 07/31/2027 (Subcontract PI)
The Brigham and Women's Hospital, Inc. NIH NCI
1R01CA272637-01

The Conundrum of Absentee Receptors: Efficacy Potentiation Through Drug-Receptor Modulation
09/21/2022 - 06/30/2027 (PI)
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases
1R01AR081264-01

Sustained Release Relaxin-2 for the Treatment of Frozen Shoulder
08/01/2022 - 05/31/2027 (PI)
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases
1R01AR079489-01A1

Precise tumor targeting with logic CAR circuits
09/17/2021 - 08/31/2026 (Multi-PI)
PI: Mark Grinstaff, PhD
NIH/National Cancer Institute
5U01CA265713-02

Sulfated Poly-Amido-Saccharide (sulPAS) Biomaterials as Anticoagulants
07/01/2022 - 06/30/2026 (PI)
NIH/National Heart, Lung, and Blood Institute
1R01HL164650-01

Biodegradable, Biocompatible Pressure Sensitive Adhesives
08/05/2022 - 04/30/2026 (PI)
NIH/National Heart, Lung, and Blood Institute
1R01HL159644-01A1

Development of a Surgical Drug Delivery System for Enhancement of CAR T Cell Activity
09/09/2021 - 09/08/2025 (Key Person / Mentor)
NIH/National Cancer Institute
5F30CA257566-02

R21: A novel antibody-drug conjugate for treatment of squamous cell lung carcinoma
07/01/2022 - 06/30/2024 (PI)
NIH/National Cancer Institute
1R21CA273645-01

SUPERHYDROPHOBIC DRUG LOADED BUTTRESSES FOR PREVENTION OF LUNG TUMOR RECURRENCE
02/15/2019 - 01/31/2024 (PI)
NIH/National Cancer Institute
5R01CA232708-04

Showing 10 of 54 results. Show All Results


Title


Yr Title Project-Sub Proj Pubs
2023 OPTIMIZATION OF NANOPARTICLE TUMOR-LOCALIZATION AND DRUG-LOADINGFOR TREATING MESOTHELIOMA 5R01CA232056-05
2022 The Conundrum of Absentee Receptors: Efficacy Potentiation Through Drug-Receptor Modulation 1R01AR081264-01
2022 Biodegradable, Biocompatible Pressure Sensitive Adhesives 1R01HL159644-01A1
2022 Sustained Release Relaxin-2 for the Treatment of Frozen Shoulder 1R01AR079489-01A1
2022 Supratherapeutic PTX Buttresses Reduce Locoregional Recurrence Rates Following Surgery for Soft Tissue Sarcomas 1R01CA272637-01
2022 R21: A novel antibody-drug conjugate for treatment of squamous cell lung carcinoma 1R21CA273645-01
2022 Sulfated Poly-Amido-Saccharide (sulPAS) Biomaterials as Anticoagulants 1R01HL164650-01
2022 SUPERHYDROPHOBIC DRUG LOADED BUTTRESSES FOR PREVENTION OF LUNGTUMOR RECURRENCE 5R01CA232708-04
2022 OPTIMIZATION OF NANOPARTICLE TUMOR-LOCALIZATION AND DRUG-LOADINGFOR TREATING MESOTHELIOMA 5R01CA232056-04
2022 TUMOR SPECIFIC DELIVERY OF VERTICILLIN A OVERCOMES EPIGENETIC SILENCING RESPONSIBLE FOR DRUG RESISTANCE 5R01CA227433-05
Showing 10 of 93 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Altinbasak I, Kocak S, Colby AH, Alp Y, Sanyal R, Grinstaff MW, Sanyal A. pH-Responsive nanofiber buttresses as local drug delivery devices. Biomater Sci. 2023 Jan 31; 11(3):813-821.View Related Profiles. PMID: 36408890; PMCID: PMC9930888; DOI: 10.1039/d2bm01199a;
     
  2. Colby AH, Kirsch J, Patwa AN, Liu R, Hollister B, McCulloch W, Burdette JE, Pearce CJ, Oberliels NH, Colson YL, Liu K, Grinstaff MW. Radiolabeled Biodistribution of Expansile Nanoparticles: Intraperitoneal Administration Results in Tumor Specific Accumulation. ACS Nano. 2023 Feb 14; 17(3):2212-2221.View Related Profiles. PMID: 36701244; PMCID: PMC9933882; DOI: 10.1021/acsnano.2c08451;
     
  3. Cook KA, Martinez-Lozano E, Sheridan R, Rodriguez EK, Nazarian A, Grinstaff MW. Hydrogels for the management of second-degree burns: currently available options and future promise. Burns Trauma. 2022; 10:tkac047. PMID: 36518878; PMCID: PMC9733594; DOI: 10.1093/burnst/tkac047;
     
  4. Bressler EM, Chu NQ, Sabatelle RC, Mahvi DA, Korunes-Miller JT, Nagashima F, Ichinose F, Liu R, Grinstaff MW, Colson YL, Raut CP. Doxorubicin-Loaded Polymeric Meshes Prevent Local Recurrence after Sarcoma Resection While Avoiding Cardiotoxicity. Cancer Res. 2022 Dec 02; 82(23):4474-4484. PMID: 36169924
     
  5. Tsai LL, Fitzgerald DM, Liu R, Korunes-Miller JT, Neal E, Hung YP, Bilton S, Hata A, Grinstaff MW, Colson YL. Porous Paclitaxel Mesh Reduces Local Recurrence in Patient-Derived Xenograft Resection Model. Ann Thorac Surg. 2022 Nov 11. PMID: 36376135
     
  6. Blessing WA, Digesu CS, Liu R, Mahvi DA, Tal-Mason A, Kumar A, Hachey KJ, Colby AH, Korunes-Miller JT, Agar N, Regan MS, Shih A, Raut CP, Grinstaff MW, Colson YL. Sustained Supratherapeutic Paclitaxel Delivery Enhances Irreversible Sarcoma Cell Death. Mol Cancer Ther. 2022 Nov 03; 21(11):1663-1673.View Related Profiles. PMID: 36031342; PMCID: PMC9633561; DOI: 10.1158/1535-7163.MCT-21-0750;
     
  7. Kirsch JR, Williamson AK, Yeritsyan D, Blessing WA, Momenzadeh K, Leach TR, Williamson PM, Korunes-Miller JT, DeAngelis JP, Zurakowski D, Nazarian RM, Rodriguez EK, Nazarian A, Grinstaff MW. Minimally invasive, sustained-release relaxin-2 microparticles reverse arthrofibrosis. Sci Transl Med. 2022 Oct 12; 14(666):eabo3357. PMID: 36223449
     
  8. Sockett KA, Loffredo M, Korunes-Miller J, Varghese M, Grinstaff MW. Synthesis and characterization of carbohydrate-based biosurfactant mimetics. Carbohydr Res. 2022 Dec; 522:108697. PMID: 36272207
     
  9. Varghese M, Grinstaff MW. Beyond nylon 6: polyamides via ring opening polymerization of designer lactam monomers for biomedical applications. Chem Soc Rev. 2022 Oct 03; 51(19):8258-8275. PMID: 36047318; PMCID: PMC9856205; DOI: 10.1039/d1cs00930c;
     
  10. Scott KM, Cohen DJ, Nielson DW, Kim G, Olson LC, McClure MJ, Grinstaff MW, Boyan BD, Schwartz Z. Prophylactic administration of miR-451 inhibitor decreases osteoarthritis severity in rats. Sci Rep. 2022 Sep 27; 12(1):16068. PMID: 36167718; PMCID: PMC9513290; DOI: 10.1038/s41598-022-20415-0;
     
Showing 10 of 375 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 375 publications over 34 distinct years, with a maximum of 26 publications in 2016

YearPublications
19901
19912
19922
19933
19944
19953
19962
19972
19982
19998
20006
20016
20029
20035
20047
20059
200612
20076
200817
200910
201014
201118
201219
201319
201412
201517
201626
201719
201824
201925
202021
202121
202222
20232


2012 National Academy of Inventors Charter Fellow
2012 Kern Faculty Fellow
2011 Stevenson Biomaterials Lecturer, Syracuse Biomaterials Institute, Syracuse University
2010 Boston University Innovator of the Year
2010 Elected to AIMBE (College of Fellows of the American Institute for Medical & Biomedical Engineering)
2010 Professeur Invité and Certificat sur Honneur, Université de Bordeaux (Bordeaux II)
2009 COE Distinguished Faculty Fellow (5-year Endowed Fellowship)
2008 Edward M. Kennedy Award for Health Care Innovation
2007 Professeurr Invité and Certificat sur Honneur, Université de la Maditerranée (Aix-Marseille II)
2006 Elected Fellow of the American Academy of Nanomedicine
2001 3M Non-Tenured Faculty Award
2001 Johnson and Johnson Focused Giving Grant Recipient
2000 Camille Dreyfus Teacher-Scholar
2000 Alfred P. Sloan Research Fellowship
1999 Pew Scholar in the Biomedical Sciences
1999 NSF Career Award
1998 Whitaker Foundation Grant Recipient
1994 ACS Nobel Laureate Signature Award
1993 NIH Postdoctoral Fellowship
1991 T.S. Piper Award for Outstanding Inorganic Research
1990 The ACS Fellowship of the Colloid & Surface Division (Sponsored by Procter & Gamble)
1989 University of Illinois Chemistry Department Fellowship
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Biomaterials
Drug Delivery
Macromolecular Chemistry and Engineering
Nanodevices
Self-Assembly
Tissue Engineering
Contact for Mentoring:

590 Commonwealth Ave
Boston MA 02215
Google Map


Grinstaff's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_